Wang et al. evaluated the efficacy and safety of specific interleukin (IL)-1 inhibitors, specific IL-6 inhibitors, and GM-CSF blockades in the treatment of COVID-19 patients (on the verge of sepsis) through systematic review and meta-analysis. This evidence concerns the gene IL1A and Sepsis.